Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: GlobeNewswire
On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second quarter, with enrollment continuing ahead of schedule Enrollment on track in Phase 2 SKYWAY basket trial evaluating TL1A inhibition in rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA"), with fourth quarter readouts expected in each sub-study Strengthened the balance sheet with an underwritten public offering of common stock in October 2025 and announced the appointment of Kate Tansey Chevlen as Chief Commercial Officer (CCO) $757 million of cash, cash equivalents, and marketable securities as of December 31, 2025, with expected runway into the second half of 2028 WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-act
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics to Participate in Upcoming March Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics to Participate in Upcoming March Investor ConferencesGlobeNewswire
- Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Leerink Partners to a "strong-buy" rating.MarketBeat
- Spyre Therapeutics (NASDAQ:SYRE) had its price target raised by analysts at Wells Fargo & Company from $40.00 to $50.00. They now have an "overweight" rating on the stock.MarketBeat
- Spyre Therapeutics (NASDAQ:SYRE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $70.00 price target on the stock.MarketBeat
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 2/27/26 - Form POS
- 2/19/26 - Form S-3
- 2/19/26 - Form S-8
- SYRE's page on the SEC website